Chronic ACE inhibition by quinapril modulates central vasopressinergic system

Frank Muders, Dietmar Elsner, Karin Jandeleit, Udo Bahner, Eckhard P. Kromer, Ingrid Kirst, Günter A.J. Riegger, M. Palkóvits

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: The role of the brain as a target for angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure and hypertension is unclear. To test the hypothesis that ACE inhibitors may modulate other central neuropeptide systems such as the central vasopressin system, we studied the effects of chronic treatment with the ACE inhibitor, quinapril, on ACE activity and on central vasopressin content in specific brain areas in rats. Methods: 22 rats were chronically treated with quinapril (6 mg · kg- 1 BW per garage daily for 6 weeks; untreated controls, n = 14). ACE density in various brain regions was assessed by in vitro autoradiography using the specific ACE inhibitor, 125I-351A. Vasopressin content was determined in 19 brain areas (micropunch technique) known to be involved in cardiovascular regulation. Results: Following chronic quinapril treatment ACE was significantly decreased in the thalamus (- 38%), hypothalamus (- 37%), hypophysis (- 35%), cerebellum (- 36%), choroid plexus (- 20%), and locus coeruleus (- 35%). Additionally, a marked reduction in serum ACE activity (- 97%) was observed. Plasma levels of vasopressin were significantly decreased after quinapril treatment (0.97[s.e.m. 0.11] vs. 1.63[0.24] pg · ml-1 in controls, P <0.05). Vasopressin content was significantly reduced in 9 of 19 specific brain areas. Regarding the hypothalamic vasopressin-producing nuclei, vasopressin was decreased in the paraventricular (292[197] vs. 2379[585] pg · mg-1 protein in controls; P -1 protein; P <0.05), but not in the suprachiasmatic nucleus. Vasopressin content was significantly reduced in brain areas connected by vasopressinergic fibres originating in the hypothalamic paraventricular nucleus: namely central gray, subcommissural organ, organum vasculosum laminae terminalis, dorsal raphe nucleus, and locus coeruleus. Vasopressin content was also significantly reduced in the median eminence (5887[1834] vs. 28321[4969] pg · mg-1 protein, P <0.001), where the hormone is mainly concentrated in the hypothalamo-hypophysial tract. Conclusions: Autoradiographic studies in vitro indicate that orally administered quinapril suppresses central ACE activity after chronic treatment. ACE inhibition by quinapril strongly influences vasopressin content in important brain areas which are involved in central cardiovascular regulation. Therefore, central modulatory effects of ACE inhibitors may also contribute to overall therapeutic efficacy.

Original languageEnglish
Pages (from-to)575-581
Number of pages7
JournalCardiovascular Research
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 1997

Fingerprint

Peptidyl-Dipeptidase A
Vasopressins
Angiotensin-Converting Enzyme Inhibitors
Brain
Locus Coeruleus
Subcommissural Organ
quinapril
Median Eminence
Suprachiasmatic Nucleus
Proteins
Choroid Plexus
Paraventricular Hypothalamic Nucleus
Pituitary Gland
Neuropeptides
Autoradiography
Treatment Failure
Thalamus
Cerebellum
Hypothalamus
Heart Failure

Keywords

  • ACE
  • ACE inhibitors
  • Brain nuclei
  • Central cardiovascular regulation
  • Rat
  • Vasopressin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chronic ACE inhibition by quinapril modulates central vasopressinergic system. / Muders, Frank; Elsner, Dietmar; Jandeleit, Karin; Bahner, Udo; Kromer, Eckhard P.; Kirst, Ingrid; A.J. Riegger, Günter; Palkóvits, M.

In: Cardiovascular Research, Vol. 34, No. 3, 06.1997, p. 575-581.

Research output: Contribution to journalArticle

Muders, F, Elsner, D, Jandeleit, K, Bahner, U, Kromer, EP, Kirst, I, A.J. Riegger, G & Palkóvits, M 1997, 'Chronic ACE inhibition by quinapril modulates central vasopressinergic system', Cardiovascular Research, vol. 34, no. 3, pp. 575-581. https://doi.org/10.1016/S0008-6363(97)00084-9
Muders F, Elsner D, Jandeleit K, Bahner U, Kromer EP, Kirst I et al. Chronic ACE inhibition by quinapril modulates central vasopressinergic system. Cardiovascular Research. 1997 Jun;34(3):575-581. https://doi.org/10.1016/S0008-6363(97)00084-9
Muders, Frank ; Elsner, Dietmar ; Jandeleit, Karin ; Bahner, Udo ; Kromer, Eckhard P. ; Kirst, Ingrid ; A.J. Riegger, Günter ; Palkóvits, M. / Chronic ACE inhibition by quinapril modulates central vasopressinergic system. In: Cardiovascular Research. 1997 ; Vol. 34, No. 3. pp. 575-581.
@article{5187377a6e5d4e75acc6c2d2a70e1aa8,
title = "Chronic ACE inhibition by quinapril modulates central vasopressinergic system",
abstract = "Objective: The role of the brain as a target for angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure and hypertension is unclear. To test the hypothesis that ACE inhibitors may modulate other central neuropeptide systems such as the central vasopressin system, we studied the effects of chronic treatment with the ACE inhibitor, quinapril, on ACE activity and on central vasopressin content in specific brain areas in rats. Methods: 22 rats were chronically treated with quinapril (6 mg · kg- 1 BW per garage daily for 6 weeks; untreated controls, n = 14). ACE density in various brain regions was assessed by in vitro autoradiography using the specific ACE inhibitor, 125I-351A. Vasopressin content was determined in 19 brain areas (micropunch technique) known to be involved in cardiovascular regulation. Results: Following chronic quinapril treatment ACE was significantly decreased in the thalamus (- 38{\%}), hypothalamus (- 37{\%}), hypophysis (- 35{\%}), cerebellum (- 36{\%}), choroid plexus (- 20{\%}), and locus coeruleus (- 35{\%}). Additionally, a marked reduction in serum ACE activity (- 97{\%}) was observed. Plasma levels of vasopressin were significantly decreased after quinapril treatment (0.97[s.e.m. 0.11] vs. 1.63[0.24] pg · ml-1 in controls, P <0.05). Vasopressin content was significantly reduced in 9 of 19 specific brain areas. Regarding the hypothalamic vasopressin-producing nuclei, vasopressin was decreased in the paraventricular (292[197] vs. 2379[585] pg · mg-1 protein in controls; P -1 protein; P <0.05), but not in the suprachiasmatic nucleus. Vasopressin content was significantly reduced in brain areas connected by vasopressinergic fibres originating in the hypothalamic paraventricular nucleus: namely central gray, subcommissural organ, organum vasculosum laminae terminalis, dorsal raphe nucleus, and locus coeruleus. Vasopressin content was also significantly reduced in the median eminence (5887[1834] vs. 28321[4969] pg · mg-1 protein, P <0.001), where the hormone is mainly concentrated in the hypothalamo-hypophysial tract. Conclusions: Autoradiographic studies in vitro indicate that orally administered quinapril suppresses central ACE activity after chronic treatment. ACE inhibition by quinapril strongly influences vasopressin content in important brain areas which are involved in central cardiovascular regulation. Therefore, central modulatory effects of ACE inhibitors may also contribute to overall therapeutic efficacy.",
keywords = "ACE, ACE inhibitors, Brain nuclei, Central cardiovascular regulation, Rat, Vasopressin",
author = "Frank Muders and Dietmar Elsner and Karin Jandeleit and Udo Bahner and Kromer, {Eckhard P.} and Ingrid Kirst and {A.J. Riegger}, G{\"u}nter and M. Palk{\'o}vits",
year = "1997",
month = "6",
doi = "10.1016/S0008-6363(97)00084-9",
language = "English",
volume = "34",
pages = "575--581",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Chronic ACE inhibition by quinapril modulates central vasopressinergic system

AU - Muders, Frank

AU - Elsner, Dietmar

AU - Jandeleit, Karin

AU - Bahner, Udo

AU - Kromer, Eckhard P.

AU - Kirst, Ingrid

AU - A.J. Riegger, Günter

AU - Palkóvits, M.

PY - 1997/6

Y1 - 1997/6

N2 - Objective: The role of the brain as a target for angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure and hypertension is unclear. To test the hypothesis that ACE inhibitors may modulate other central neuropeptide systems such as the central vasopressin system, we studied the effects of chronic treatment with the ACE inhibitor, quinapril, on ACE activity and on central vasopressin content in specific brain areas in rats. Methods: 22 rats were chronically treated with quinapril (6 mg · kg- 1 BW per garage daily for 6 weeks; untreated controls, n = 14). ACE density in various brain regions was assessed by in vitro autoradiography using the specific ACE inhibitor, 125I-351A. Vasopressin content was determined in 19 brain areas (micropunch technique) known to be involved in cardiovascular regulation. Results: Following chronic quinapril treatment ACE was significantly decreased in the thalamus (- 38%), hypothalamus (- 37%), hypophysis (- 35%), cerebellum (- 36%), choroid plexus (- 20%), and locus coeruleus (- 35%). Additionally, a marked reduction in serum ACE activity (- 97%) was observed. Plasma levels of vasopressin were significantly decreased after quinapril treatment (0.97[s.e.m. 0.11] vs. 1.63[0.24] pg · ml-1 in controls, P <0.05). Vasopressin content was significantly reduced in 9 of 19 specific brain areas. Regarding the hypothalamic vasopressin-producing nuclei, vasopressin was decreased in the paraventricular (292[197] vs. 2379[585] pg · mg-1 protein in controls; P -1 protein; P <0.05), but not in the suprachiasmatic nucleus. Vasopressin content was significantly reduced in brain areas connected by vasopressinergic fibres originating in the hypothalamic paraventricular nucleus: namely central gray, subcommissural organ, organum vasculosum laminae terminalis, dorsal raphe nucleus, and locus coeruleus. Vasopressin content was also significantly reduced in the median eminence (5887[1834] vs. 28321[4969] pg · mg-1 protein, P <0.001), where the hormone is mainly concentrated in the hypothalamo-hypophysial tract. Conclusions: Autoradiographic studies in vitro indicate that orally administered quinapril suppresses central ACE activity after chronic treatment. ACE inhibition by quinapril strongly influences vasopressin content in important brain areas which are involved in central cardiovascular regulation. Therefore, central modulatory effects of ACE inhibitors may also contribute to overall therapeutic efficacy.

AB - Objective: The role of the brain as a target for angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure and hypertension is unclear. To test the hypothesis that ACE inhibitors may modulate other central neuropeptide systems such as the central vasopressin system, we studied the effects of chronic treatment with the ACE inhibitor, quinapril, on ACE activity and on central vasopressin content in specific brain areas in rats. Methods: 22 rats were chronically treated with quinapril (6 mg · kg- 1 BW per garage daily for 6 weeks; untreated controls, n = 14). ACE density in various brain regions was assessed by in vitro autoradiography using the specific ACE inhibitor, 125I-351A. Vasopressin content was determined in 19 brain areas (micropunch technique) known to be involved in cardiovascular regulation. Results: Following chronic quinapril treatment ACE was significantly decreased in the thalamus (- 38%), hypothalamus (- 37%), hypophysis (- 35%), cerebellum (- 36%), choroid plexus (- 20%), and locus coeruleus (- 35%). Additionally, a marked reduction in serum ACE activity (- 97%) was observed. Plasma levels of vasopressin were significantly decreased after quinapril treatment (0.97[s.e.m. 0.11] vs. 1.63[0.24] pg · ml-1 in controls, P <0.05). Vasopressin content was significantly reduced in 9 of 19 specific brain areas. Regarding the hypothalamic vasopressin-producing nuclei, vasopressin was decreased in the paraventricular (292[197] vs. 2379[585] pg · mg-1 protein in controls; P -1 protein; P <0.05), but not in the suprachiasmatic nucleus. Vasopressin content was significantly reduced in brain areas connected by vasopressinergic fibres originating in the hypothalamic paraventricular nucleus: namely central gray, subcommissural organ, organum vasculosum laminae terminalis, dorsal raphe nucleus, and locus coeruleus. Vasopressin content was also significantly reduced in the median eminence (5887[1834] vs. 28321[4969] pg · mg-1 protein, P <0.001), where the hormone is mainly concentrated in the hypothalamo-hypophysial tract. Conclusions: Autoradiographic studies in vitro indicate that orally administered quinapril suppresses central ACE activity after chronic treatment. ACE inhibition by quinapril strongly influences vasopressin content in important brain areas which are involved in central cardiovascular regulation. Therefore, central modulatory effects of ACE inhibitors may also contribute to overall therapeutic efficacy.

KW - ACE

KW - ACE inhibitors

KW - Brain nuclei

KW - Central cardiovascular regulation

KW - Rat

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=0030905325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030905325&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(97)00084-9

DO - 10.1016/S0008-6363(97)00084-9

M3 - Article

C2 - 9231041

AN - SCOPUS:0030905325

VL - 34

SP - 575

EP - 581

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -